David J Stewart

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer
    David J Stewart
    The Ottawa Regional Cancer Centre, Cancer Care Ontario, Ottawa, Ontario, Canada
    Lung Cancer 44:241-9. 2004
  2. pmc Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Crit Rev Oncol Hematol 75:173-234. 2010
  3. ncbi Equipoise lost: ethics, costs, and the regulation of cancer clinical research
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2925-35. 2010
  4. pmc Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 5:1826-34. 2010
  5. pmc Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
    Lung Cancer 71:217-23. 2011
  6. ncbi Mechanisms of resistance to cisplatin and carboplatin
    David J Stewart
    Section of Experimental Therapeutics, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Crit Rev Oncol Hematol 63:12-31. 2007
  7. ncbi Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms
    David J Stewart
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Treat Rev 33:101-37. 2007
  8. ncbi Foreword--new directions for topotecan in lung cancer treatment
    David J Stewart
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Room FC 9 3062, Houston, Texas 77030, USA
    Oncologist 9:1-3. 2004
  9. ncbi Topotecan in the first-line treatment of small cell lung cancer
    David J Stewart
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Room FC 9 3062, Houston, Texas 77030, USA
    Oncologist 9:33-42. 2004
  10. ncbi Update on the role of topotecan in the treatment of non-small cell lung cancer
    David J Stewart
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0432, Houston, Texas 77030, USA
    Oncologist 9:43-52. 2004

Research Grants

  1. Changes in Tumor DNA Methylation with Decitabine
    David Stewart; Fiscal Year: 2006

Collaborators

Detail Information

Publications55

  1. ncbi Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer
    David J Stewart
    The Ottawa Regional Cancer Centre, Cancer Care Ontario, Ottawa, Ontario, Canada
    Lung Cancer 44:241-9. 2004
    ..We assessed the use of alternating drugs with differing mechanisms of action as treatment for advanced non-small cell lung cancer...
  2. pmc Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Crit Rev Oncol Hematol 75:173-234. 2010
    ..To date, resistance-modulating strategies have generally not proven clinically useful in lung cancer, although small randomized trials suggest a modest benefit of verapamil and related agents in NSCLC...
  3. ncbi Equipoise lost: ethics, costs, and the regulation of cancer clinical research
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2925-35. 2010
    ..We outline suggested solutions...
  4. pmc Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 5:1826-34. 2010
    ..Some studies (but not others) suggested that high doses are beneficial in small cell lung cancer (SCLC). We hypothesized that dose-response curve (DRC) shape reflects resistance mechanisms...
  5. pmc Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer
    David J Stewart
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
    Lung Cancer 71:217-23. 2011
    ..We conducted a preliminary feasibility assessment of EDNRA of patient survival curves...
  6. ncbi Mechanisms of resistance to cisplatin and carboplatin
    David J Stewart
    Section of Experimental Therapeutics, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Crit Rev Oncol Hematol 63:12-31. 2007
    ....
  7. ncbi Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms
    David J Stewart
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Treat Rev 33:101-37. 2007
    ....
  8. ncbi Foreword--new directions for topotecan in lung cancer treatment
    David J Stewart
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Room FC 9 3062, Houston, Texas 77030, USA
    Oncologist 9:1-3. 2004
  9. ncbi Topotecan in the first-line treatment of small cell lung cancer
    David J Stewart
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Room FC 9 3062, Houston, Texas 77030, USA
    Oncologist 9:33-42. 2004
    ..Additional clinical trials to investigate topotecan-based combination regimens and confirm their role in the first-line treatment of SCLC are under way...
  10. ncbi Update on the role of topotecan in the treatment of non-small cell lung cancer
    David J Stewart
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0432, Houston, Texas 77030, USA
    Oncologist 9:43-52. 2004
    ..Herein, the future role of topotecan in the first- and second-line treatment of NSCLC and the potential role of resistance mechanisms obtained from in vivo dose-response studies in designing future combination regimens are discussed...
  11. doi Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas
    David J Stewart
    M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:3881-8. 2009
    ..By hypomethylating genes, decitabine may up-regulate factors required for chemotherapeutic cytotoxicity. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1...
  12. pmc Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy
    Apar Pataer
    Departments of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 7:825-32. 2012
    ....
  13. pmc Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy
    Xifeng Wu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1340, Houston, TX 77030, USA
    J Natl Cancer Inst 103:817-25. 2011
    ..Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC)...
  14. pmc Tissue platinum concentration and tumor response in non-small-cell lung cancer
    Eric S Kim
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA
    J Clin Oncol 30:3345-52. 2012
    ..We assessed the effects of tissue platinum concentrations on response and survival in NSCLC...
  15. ncbi Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC
    George R Blumenschein
    University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Biomark 10:287-98. 2011
    ....
  16. doi Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:2409-15. 2010
    ..A phase 2 trial was conducted to estimate the efficacy of this regimen in previously untreated patients with extensive SCLC...
  17. pmc Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer
    Moubin Lin
    Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 32:1050-6. 2011
    ..These results suggest that genetic variations in the TGF-β pathway are potential predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy with or without radiation...
  18. ncbi Genetic variants in cell cycle control pathway confer susceptibility to lung cancer
    Wei Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5974-81. 2007
    ..To test the hypothesis that common sequence variants of cell cycle control genes may affect lung cancer predisposition...
  19. pmc Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer
    Michelle A T Hildebrandt
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e12402. 2010
    ..These results suggest that genetic variations among inflammation pathway genes may modulate the development of radiation-induced toxicity and, ultimately, help in identifying patients who are at an increased likelihood for such events...
  20. pmc Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 33:1699-706. 2012
    ..Future studies are needed to identify the causal SNPs and elucidate the underlying molecular mechanisms...
  21. pmc Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans
    Charles Lu
    The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e34833. 2012
    ..No drug strategies currently exist targeting loss-of-function genetic abnormalities. We report the first in-human systemic gene therapy clinical trial of tumor suppressor gene TUSC2...
  22. doi Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:2104-11. 2011
    ..Baseline tumor specimens, serum, and perfusion computed tomography (CT) scans were obtained for supportive evaluation...
  23. pmc Phase II study of dasatinib in patients with advanced non-small-cell lung cancer
    Faye M Johnson
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:4609-15. 2010
    ..We tested the hypotheses that the activation of epidermal growth factor receptor (EGFR) or SFK or modulation of serum cytokines may predict a response to dasatinib...
  24. ncbi Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
    Eric S Kim
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA Electronic address
    Lung Cancer 85:88-93. 2014
    ..We investigated the relationship between tissue platinum concentrations and CTR1 expression in NSCLC specimens...
  25. pmc EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma
    Carmen Behrens
    Authors Affiliations Departments of Thoracic Head and Neck Medical Oncology, Pathology, Biostatistics, Thoracic Surgery, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas and The University of Ottawa, Ottawa, Canada
    Clin Cancer Res 19:6556-65. 2013
    ..We studied EZH2 expression by immunohistochemistry in a large series of non-small cell lung carcinomas (NSCLC) in association with tumor characteristics and patient outcomes...
  26. ncbi Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial
    George R Blumenschein
    Authors Affiliations Departments of Thoracic Head and Neck Medical Oncology, Biostatistics and Applied Mathematics, Translational Molecular Pathology, Diagnostic Imaging, Diagnostic Radiology, and Bioinformatics and Computational Biology Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston The Hamon Center for Therapeutic Oncology Research and Departments of Internal Medicine and Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Charlotte, North Carolina Medical Oncology, Yale Cancer Center, New Haven, Connecticut Division of Medical Oncology, University of Ottawa, Ottawa, Ontario Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, Baltimore, Maryland UC San Diego Moores Cancer Center, La Jolla, California and Centre de Recherche en Cancérologie de Lyon, UMR INSERM 1052 CNRS 5286, Centre Leon Berard, Lyon, France
    Clin Cancer Res 19:6967-75. 2013
    ..To report the clinical efficacy of sorafenib and to evaluate biomarkers associated with sorafenib clinical benefit in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) program...
  27. ncbi The BATTLE trial: personalizing therapy for lung cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Discov 1:44-53. 2011
    ..BATTLE establishes the feasibility of a new paradigm for a personalized approach to lung cancer clinical trials...
  28. pmc High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation
    Maria Ines Nunez
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 7:833-40. 2012
    ..Information on the protein expression of these receptors in non-small-cell lung carcinoma (NSCLC) is limited...
  29. pmc PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy
    Xia Pu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Lung Cancer 71:82-8. 2011
    ..With further validation, our findings may provide additional biomarkers for customized treatment of platinum-based chemotherapy for NSCLC...
  30. ncbi Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases
    Yun Oh
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1402, USA
    Cancer 115:2930-8. 2009
    ..The staging system for non-small cell lung cancer (NSCLC) does not consider tumor burden or number of metastatic sites, although oligometastases are more favorable...
  31. doi Sorafenib-induced premalignant and malignant skin lesions
    Victoria L Williams
    Baylor College of Medicine, Houston, TX, USA
    Int J Dermatol 50:396-402. 2011
    ..To review characteristics of patients who develop premalignant and malignant skin lesions while on sorafenib therapy and discuss implications for subsequent treatment of their primary malignancies...
  32. pmc Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib
    Banibrata Sen
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Sci Transl Med 4:136ra70. 2012
    ..Moreover, the potential synthetic lethality of combination therapy including dasatinib and BRAF inhibitors may lead to additional therapeutic options against cancers with wild-type BRAF...
  33. ncbi Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 2:745-50. 2007
    ..Preclinical data suggest that this drug might also enhance the antineoplastic effects of chemotherapy...
  34. ncbi Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis
    Jinliang Xing
    Department of Epidemiology, Unit 1340, The University of Texas M D Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 16:1517-22. 2007
    ..Additionally, cell accumulation indices at both G2-M and S phases were not associated with clinical stages. We conclude that attenuated functions of G2-M and S cell cycle checkpoints might be susceptibility markers for lung cancer...
  35. pmc DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy
    Li E Wang
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:4121-8. 2011
    ..In this larger independent study of 591 patients with NSCLC, we further evaluated whether DRC in peripheral lymphocytes predicts survival of patients with NSCLC who receive platinum-based chemotherapy...
  36. doi Targeted therapy in non-small-cell lung cancer--is it becoming a reality?
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 7:401-14. 2010
    ..Novel drugs aimed at these abnormalities are already in the clinic. This Review outlines the current state-of-the-art research for targeted therapy in NSCLC...
  37. ncbi Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer
    David J Stewart
    Division of Medical Oncology, University of Ottawa, Ottawa, Ontario, Canada and Departments of Pathiology, Biostatistics, Thoracic and Cardiovascular Surgery, Thoracic Head and Neck Medical Oncology, and Translational Molecular Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas
    J Thorac Oncol 9:675-84. 2014
    ..Adjuvant chemotherapy reduces recurrences of non-small-cell lung cancer (NSCLC). To determine which patients need adjuvant chemotherapy, we assessed factors associated with time to relapse (TTR)...
  38. doi Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009
    Filip Janku
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6356-63. 2012
    ..We analyzed the outcomes of single-agent phase II clinical trials in non-small cell lung cancer (NSCLC) to determine trial parameters that predicted clinical activity...
  39. doi Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer
    George R Blumenschein
    The M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030 4009, USA
    J Clin Oncol 27:4274-80. 2009
    ..We evaluated the antitumor response and tolerability of sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer (NSCLC), most of whom had received prior platinum-based chemotherapy...
  40. ncbi Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy
    Ozden Altundag
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 2:141-6. 2007
    ..43). Hematologic and nonhematologic toxicities were similar. Our data indicate that selected patients 80 years of age and older may tolerate and benefit from chemotherapy, and prospective evaluation of these patients is indicated...
  41. doi Wnt signaling pathway in non-small cell lung cancer
    David J Stewart
    Affiliation of author Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada
    J Natl Cancer Inst 106:djt356. 2014
    ..Wnt pathway antagonists warrant exploration clinically in NSCLC. Agents blocking selected specific β-catenin interactions and approaches to increase expression of downregulated Wnt inhibitors may be of particular interest. ..
  42. pmc Fool's gold, lost treasures, and the randomized clinical trial
    David J Stewart
    Division of Medical Oncology, The University of Ottawa, Ottawa, Canada
    BMC Cancer 13:193. 2013
    ..The high costs of randomized clinical trials slow progress (thereby causing avoidable loss of life) and increase health care costs...
  43. ncbi Novel therapeutic targets in non-small cell lung cancer
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:1601-12. 2011
    ..This review describes molecular targets in non-small cell lung cancer that are in development or being clinically applied and their implications for developing novel anticancer therapies for this previously refractory malignancy...
  44. ncbi Systemic therapy for lung cancer brain metastases: a rationale for clinical trials
    Yun Oh
    Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 22:168-78; discussion 178, 183, 188 passim. 2008
    ..This collective information describes an area in need of therapeutic development and supports an initiative to evaluate novel targeted therapies for lung cancer brain metastases...
  45. pmc Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features
    Luisa M Solis
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:3743-53. 2010
    ....
  46. doi Potential of CXCR4 antagonists for the treatment of metastatic lung cancer
    Jan A Burger
    Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Expert Rev Anticancer Ther 11:621-30. 2011
    ..In addition, we review the current status of the preclinical and clinical development of CXCR4 antagonists...
  47. pmc ATM sequence variants associate with susceptibility to non-small cell lung cancer
    Hushan Yang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX
    Int J Cancer 121:2254-9. 2007
    ....
  48. ncbi CXCR4 chemokine receptor antagonists: perspectives in SCLC
    Jan A Burger
    University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX 77230 1402, USA
    Expert Opin Investig Drugs 18:481-90. 2009
    ..Here, we summarize preclinical data about CXCR4 in SCLC, and the current status of the preclinical and clinical development of CXCR4 antagonists...
  49. doi Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial
    Apostolia Maria Tsimberidou
    The University of Texas M D Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:6243-50. 2009
    ..However, several oncology drugs have been approved on the basis of objective end points without a randomized trial. We reviewed the long-term safety and efficacy of such agents...
  50. ncbi Imaging of the patient with non-small cell lung cancer
    Reginald F Munden
    Division of Diagnostic Imaging, Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiology 237:803-18. 2005
    ..This article reviews the role of imaging in patients with non-small cell lung cancer, with an emphasis on the radiologic imaging findings relevant for each specialty...
  51. ncbi U.s. Food and drug administration inspections of clinical investigators: overview of results from 1977 to 2009
    Sonia K Morgan-Linnell
    Authors Affiliations Department of Investigational Cancer Therapeutics Phase I Program, University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:3364-70. 2014
    ..The vast majority of FDA inspections yield deficiency findings and, as a result, only about one third of inspections have an outcome of "no action indicated." Clin Cancer Res; 20(13); 3364-70. ©2014 AACR. ..
  52. doi Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer
    David J Stewart
    J Natl Cancer Inst 100:445-6; author reply 446. 2008
  53. doi Gefitinib maintenance in stage III non-small-cell lung cancer
    David J Stewart
    J Clin Oncol 26:4849-50; author reply 4850-1. 2008
  54. doi Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer
    Edith M Marom
    Department of Diagnostic Imaging, University of Texas, M D Anderson Cancer Center, Sheba Medical Center, Tel Hashomer, Israel
    J Thorac Oncol 3:351-7. 2008
    ....
  55. ncbi Combining epigenetic and cytotoxic therapy in the treatment of solid tumors
    Elizabeth R Plimack
    J Clin Oncol 25:4519-21. 2007

Research Grants1

  1. Changes in Tumor DNA Methylation with Decitabine
    David Stewart; Fiscal Year: 2006
    ..This preliminary look at individual genes may provide a molecular rationale for future decitabine therapeutic studies in specific relevant tumor types. ..